Tuberculosis with Drug-Induced Hepatitis: A Narrative Literature Review
DOI:
https://doi.org/10.37275/bsm.v8i2.929Keywords:
Antituberculosis drugs, Abdominal pain, Drug induced hepatitis, Hepatomegaly, JaundiceAbstract
Tuberculosis (TB) is an infectious disease that is a global health problem. The problem is that 5-28% of patients receiving tuberculosis treatment suffer from drug-induced hepatitis on antituberculosis drugs (OAT). The clinical picture should be differentiated from other liver diseases. The level of symptoms varies from asymptomatic to symptomatic, such as nausea, vomiting, abdominal pain, jaundice, hepatomegaly, and increased liver function. OAT use is stopped if clinical symptoms are found and ALT/AST increases ≥3 times, or if there are no symptoms but there is an increase in bilirubin ≥2 mg/dl or ALT/AST values ≥5 times without clinical symptoms. The use of OAT can be continued, but with supervision, if there are no clinical symptoms and the increase in ALT/AST is <2 times and the bilirubin value is <2 mg/dl. Treatment can be carried out again by reintroducing OATs one by one according to ATS recommendations.
Authors
- Riska Yuliana Sari1*
- Zarfiardy Aksa Fauzi1
- 1Department of Pulmonology and Respirology Medicine, Medical Faculty, University of Riau, Pekanbaru, Indonesia
Corresponding author Riska Yuliana Sari — riskanyrosiy14@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
